Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation

BMC Hematology

Hubertus Axer²  Andreas Hochhaus³  Otto W Witte²  Klas Böer¹  Herbert G Sayer³  Andreas Ragoschke-Schumm⁴  Mike Reinhöfer¹  Mary Fuchs² 

[1]Department of Clinical Chemistry and Laboratory Diagnostics, Jena University Hospital, Erlanger Allee 101, D-07747 Jena, Germany

[2]Hans Berger Department of Neurology, Jena University Hospital, Erlanger Allee 101, D-07747 Jena, Germany

[3]Department for Hematology and Oncology, Clinic for Internal Medicine II, Jena University Hospital, D-07747 Jena, Germany

[4]Institute of Diagnostic and Interventional Radiology, Department of Neuroradiology, Friedrich-Schiller-University Jena, Erlanger Allee 101, D-07747 Jena, Germany

关键词: BCR-ABL;    CNS relapse;    Chronic myeloid leukemia;   

Others  :  865393
DOI  :  10.1186/1471-2326-12-9

 received in 2012-03-11, accepted in 2012-08-01,  发布年份 2012

【 摘 要 】

Background

This case report highlights the relevance of quantifying the BCR-ABL gene in cerebrospinal fluid of patients with suspected relapse of chronic myeloid leukemia in the central nervous system.

Case presentation

We report on a female patient with isolated central nervous system relapse of chronic myeloid leukemia (CML) during peripheral remission after allogeneic hematopoietic stem cell transplantation. The patient showed a progressive cognitive decline as the main symptom. MRI revealed a hydrocephalus and an increase in cell count in the cerebrospinal fluid (CSF) with around 50% immature blasts in the differential count. A highly elevated BCR-ABL/ ABL ratio was detected in the CSF, whilst the ratio for peripheral blood and bone marrow was not altered. On treatment of the malresorptive hydrocephalus with shunt surgery, the patient showed an initial cognitive improvement, followed by a secondary deterioration. At this time, the cranial MRI showed leukemic infiltration of lateral ventricles walls. Hence, intrathecal administration of cytarabine, methotrexate, and dexamethasone was initiated, which caused a significant decrease of cells in the CSF. Soon after, the patient demonstrated significant cognitive improvement with a good participation in daily activities. At a later time point, after the patient had lost the major molecular response of CML, therapy with dasatinib was initiated. In a further follow-up, the patient was neurologically and hematologically stable.

Conclusions

In patients with treated CML, the rare case of an isolated CNS blast crisis has to be taken into account if neurological symptoms evolve. The analysis of BCR-ABL in the CSF is a further option for the reliable detection of primary isolated relapse of CML in these patients.

【 授权许可】

   
2012 Fuchs et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Lange T, Deininger M, Brand R, Hegenbart U, Al-Ali H, Krahl R, et al.: BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning. Leukemia 2004, 18:1468-1475.
• [2]Rajappa S, Uppin SG, Raghunadharao D, Rao IS, Surath A: Isolated central nervous system blast crisis in chronic myeloid leukemia. Hematol Oncol 2004, 22:179-181.
• [3]Kim HJ, Jung CW, Kim K, Ahn JS, Kim WS, Park K, et al.: Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib. J Clin Oncol 2006, 24:4028-4029.
• [4]Altintas A, Cil T, Kilinc I, Kaplan MA, Ayyildiz O: Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. J Neurooncol 2007, 84:103-105.
• [5]Porkka K, Koskenvesa P, Lundán T, Rimpiläinen J, Mustjoki S, Smykla R, et al.: Dasatinib crosses the blood–brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008, 112:1005-1012.
• [6]Aftimos P, Nasr F: Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature. Leuk Res 2009, 33:e178-e180.
• [7]Oshima K, Kanda Y, Yamashita T, Takahashi S, Mori T, Nakaseko C, et al.: Central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:1100-1107.